Table 2.
Characteristics of the study patients, per group.
| Improved LTF group (n = 12) | Non-improved LTF group (n = 13) | P value | |
|---|---|---|---|
| Age (years) | 72.0 ± 8.3 (73.5: 56–84) | 75.6 ± 7.8 (72: 64–93) | 0.73 |
| Sex ratio (M/F) | 5/7 | 8/5 | 0.32 |
| Disease duration (years) | 4.6 ± 5.3 (2: 1–19) | 5.2 ± 4.3 (5: 0–15) | 0.65 |
| mH&Y score | 2.9 ± 0.5 (3: 2–4) | 2.6 ± 0.4 (2.5: 2–3) | 0.14 |
| UPDRS I score | 1.3 ± 1.5 (0.5: 0–5) | 1.6 ± 1.6 (1: 0–6) | 0.54 |
| UPDRS II score | 5.3 ± 4.2 (6: 0–12) | 8.2 ± 2.9 (8: 3–13) | 0.11 |
| UPDRS III score | 15.1 ± 7.6 (15: 5–30) | 12.8 ± 7.8 (13: 2–26) | 0.41 |
| UPDRS IV score | 1.0 ± 2.2 (0: 0–8) | 2.5 ± 2.3 (1: 0–7) | 0.03 |
| UPDRS total score | 22.7 ± 12.1 (22: 5–43) | 25.2 ± 11.7 (24: 7–46) | 0.57 |
| MMSE score | 28.0 ± 2.2 (28.5: 23–30) | 27.6 ± 2.2 (27: 24–30) | 0.69 |
| MoCa-J score | 22.8 ± 3.4 (23.5: 16–28) | 24.0 ± 3.5 (24: 15–29) | 0.47 |
| FAB score | 15.2 ± 2.1 (15: 11–18) | 14.7 ± 1.6 (15: 12–17) | 0.50 |
| FTF (°) | 12.2 ± 8.5 (10.5: 2–33) | 13.2 ± 7.4 (12: 4–30) | 0.69 |
| LTF (°) | 7.5 ± 7.6 (4.5: 1–26) | 3.8 ± 4.5 (2: 1–18) | 0.05 |
| SPV angle (°) | 4.9 ± 4.4 (3.3: 1.5–17.8) | 4.3 ± 2.3 (3.5: 1.5–8.2) | 0.94 |
| LEDD (mg) | 523.9 ± 262.7 (437.5: 150–1031.8) | 667.2 ± 351.8 (560.0: 300–1515.5) | 0.32 |
| LEDDDA (mg) | 223.3 ± 220.0 (211.4: 0–618.8) | 205.1 ± 284.4 (150: 0–865.5) | 0.57 |
Significant values in bold.
Mean ± SD (median: range) values are shown, unless otherwise indicated.
mH&Y modified Hoehn and Yahr stage, UPDRS Unified Parkinson’s Disease Rating Scale, MMSE Mini-Mental State Examination, MoCa-J Japanese version of Montreal Cognitive Assessment, FAB Frontal Assessment Battery, FTF forward trunk flexion, LTF lateral trunk flexion, SPV subjective postural vertical, LEDD levodopa equivalent daily dose, LEDDDA levodopa equivalent daily dose of dopamine agonist.